Moreover, although HER2 testing is routinely performed in breast cancer, HER2 expression in gastroesophageal cancer is more heterogenous as a reflection of the distinct biology of these tumors, and as a result, the interpretation of HER2 immunohistochemistry (IHC) patterns is more complicated [6, 27, 28]. Here, ERBB2 is linked to breast cancer.